Hemophilia clinical trials

Explore recruiting hemophilia clinical trials.

Recruiting hemophilia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemophilia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

Germany, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B

Italy, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B with or without inhibitory antibodies to factor VIII or IX

France, Poland, Greece, Spain, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B

Italy, Spain, Bulgaria, Romania

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B

Germany, France, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

C3731003 Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)

Germany, Spain, France, Greece, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hemophilia trials by city

Hemophilia in Toronto Hemophilia in Vancouver Hemophilia in Montreal Hemophilia in Calgary Hemophilia in Edmonton Hemophilia in Ottawa Hemophilia in Winnipeg Hemophilia in Quebec City Hemophilia in Hamilton Hemophilia in Kitchener Hemophilia in London Hemophilia in Halifax Hemophilia in New York Hemophilia in Los Angeles Hemophilia in Chicago Hemophilia in Houston

Hemophilia clinical trials

Recruiting hemophilia studies right now

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Pharmacokinetic-guided Dosing of Emicizumab

A Study of FVIII Gene Therapy for Hemophilia A

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Embolization in Hereditary Coagulopathies

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

Manual Therapy in Hemophilic Arthropathy of the Ankle

Also recruiting in Europe

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B

A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B with or without inhibitory antibodies to factor VIII or IX

A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B

C3731003 Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)

Hemophilia trials by city

Other conditions